Management
Of all metrics mentioned, "Management" is most imperative for successful investing. Perhaps, the quality of your management isn't obvious in good times. Nevertheless, you can see how essential great management is in bad times. In my view, the management's pedigree is important but their attitude is most crucial.
If the management jumps ship at the first sign of trouble, you want to steer away from such a company. You also want management that is transparent and shareholder-friendly. In other words, that management should pick up the phone to talk to you about their stock.
Most importantly, you want to see a management that delivers what they promised. For Madrigal, the President and CEO is also an MD (i.e., Dr. Paul Friedman) which gives him added advantages in the pharmaceuticals niche. That's because he is familiar with the prescribing pattern. In light of recent developments, Dr. Friedman enthused,
We are pleased with the substantial progress the Company made in 2020, particularly in light of the significant challenges resulting from the COVID-19 pandemic. We completed enrollment in the Company’s Phase 3 MAESTRO-NAFLD-1 trial in less than 12 months, and we also made significant progress in enrollment of our Phase 3 MAESTRO-NASH trial. We advanced the development of Madrigal’s commercial capabilities in 2020, with Remy Sukhija joining the Company as Senior Vice President and Chief Commercial Officer. Remy and his team have embarked on detailed analyses of the market opportunity for resmetirom as we continue to execute our Phase 3 clinical programs.